Tumor extension
Extension of the tumor to the base of tongue reduces the chances of cure drastically. It also increases the chances of recurrence after treatment. Metastasis
Spread of cancer cells to local structures like tissues, vessels, large nerves and lymphatics worsens a patients prognosis.A study that analyzed the survival rate in HPV-related oropharynx carcinoma to that in HPV-unrelated oropharynx carcinoma. The study revealed that based on the HPV status of the patient, for STAGE III and STAGE IV oropharynx carcinoma, there was a discrepancy in survival after three years. The survival was 82% in HPV positive and then also 57% in HPV negative cancers. References


== External links ==
The German Dermatological Society indicated that Diosmin may be used with other treatments for symptoms of chronic venous diseases.The American Society of Colon and Rectal Surgeons mentions phlebotonics as a possible treatment for symptoms of hemorrhoid grades I to II, as there is only moderate-quality evidence of effectiveness with "expectations of minimal harm", while having no evidence of long-term benefit. French, Indian, Portuguese, and Italian professional societies of coloproctology issued similar recommendations regarding phlebotonics for hemorrhoids. Adverse effects
In some 10% of users, diosmin causes mild gastrointestinal disorders or skin irritations (hives, itching), stomach pain, nausea, heart arrhythmias, or anemia. Preliminary research indicates no evidence of toxicity. The US Food and Drug Administration (FDA) concluded in 2001 that there was inadequate evidence on which to base an expectation of safety. As of 2013, the FDA did not revise this position. Regulatory status
Diosmin is distributed in the U.S. as a dietary supplement called Daflon. Diosmin is not approved as a prescription drug in the United States or Europe. Phlebotonics are not approved in Germany, and are restricted in Spain only for the treatment of chronic venous diseases. See also
Daflon
Venalex


== References ==